Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis

Expert Opinion on Biological Therapy

Volumn 15, Issue 12, 2015, Pages 1727-1737

  Alunno, Alessia ^a   Carubbi, Francesco ^b   Cafaro, Giacomo ^a   Pucci, Giacomo ^a,c   Battista, Francesca ^a,c   Bartoloni, Elena ^a   Giacomelli, Roberto ^b   Schillaci, Giuseppe ^a,c   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c University Hospital of Terni   (Italy)

Author keywords

IL 17; IL 23; Psoriasis; Psoriatic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALX 0761; ANTIPSORIASIS AGENT; ATR 107; BI 655066; BIMEKIZUMAB; BRIAKINUMAB; BRODALUMAB; CNTO 6785; COVA 322; ETANERCEPT; FEZAKINUMAB; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; IXEKIZUMAB; MONOCLONAL ANTIBODY; NNC 0114 0000 0005; SECUKINUMAB; TILDRAKIZUMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; IL17A PROTEIN, HUMAN;

AUTOIMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INFECTION; INFESTATION; META ANALYSIS; MICROENVIRONMENT; NEUTROPENIA; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TH1 CELL; TH17 CELL; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; IMMUNOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; USTEKINUMAB;

EID: 84941010774     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1084284     Document Type: Review

References (74)

1. van den Berg WB, McInnes IB. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43:158-70
2. Rouvier E, Luciani MF, Mattei MG, et al. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150:5445-56
3. Yao Z, Painter SL, Fanslow WC, et al. Human IL 17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-6.. First description of IL-17 in humans.
4. Milner JD, Brenchley JM, Laurence A, et al. Impaired T (H) 17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6
5. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008;205:1551-7
6. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500
7. Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010;184:3336-40
8. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76
9. Harrington LE, Hatton RD, Mangan PR, et al. IL 17 producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.. This study first identified Th17 cell development.
10. Aggarwal S, Ghilardi N, Xie M, et al. Interleukin 23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin 17. J Biol Chem 2003;278:1910-14
11. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014;13:668-77
12. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52
13. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol 2013;13:75-87
14. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
15. Voorhees JJ. Pathophysiology of psoriasis. Annu Rev Med 1977;28:467-73
16. Gladman DD, Keystone EC, Schacter RK. Aberrations in T-cell subpopulations in patients with psoriasis and psoriatic arthritis. J Invest Dermatol 1983;80:286-90
17. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Eng J Med 1979;301:555
18. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995;95:317-27
19. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009;160:319-24
20. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
21. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30. Identification of a role for IL-23 in psoriasis.
22. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009;15:1013-15. Identification of a role for IL-21 in psoriasis.
23. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
24. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF -A in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87
25. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008;181:4733-41
26. Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 2012;304:465-9
27. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64:ii37-9
28. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7.. First evidence of the role of IL-17 in experimental arthritis.
29. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46:802-5
30. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82
31. Pickens SR, Volin MV, Mandelin AM II, et al. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010;184:3233-41
32. Chabaud M, Garnero P, Dayer JM, et al. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000;12:1092-9
33. Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61:704-13
34. van Hamburg JP, Corneth OB, Paulissen SM, et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013;72:1700-7. Identification of a role for IL-22 in synovitis.
35. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359:419-29
36. Mitra A, Raychaudhuri SK, Raychaudhuri SP. Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther 2012;14:R65
37. Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013;15:R136
38. Yoo IS, Lee JH, Song ST, et al. T-helper 17 cells: The driving force of psoriasis and psoriatic arthritis. Int J Rheum Dis 2012;15:531-7
39. Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420-9
40. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85
41. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58:2307-17
42. Gullick NJ, Evans HG, Church LD, et al. Linking power Doppler ultrasound to the presence of th17 cells in the rheumatoid arthritis joint. PLoS One 2010;5:e12516
43. Shahrara S, Huang Q, Mandelin AM II, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10:R93
44. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014;66:1272-81. Identification of a predominant role of CD8 cells in psoriatic arthritis.
45. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med 2012;18:1069-76.. First description of IL-23 expressing CD3+CD4-CD8-cells in enthesitis.
46. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2010;64:99-109
47. Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatolog Treat 2014;25:78-82
48. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94
49. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
50. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168:844-54
51. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
52. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28
53. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9
54. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological antitumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebocontrolled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9
55. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014;371:326-38. First results from Phase III studies of secukinumab in psoriasis.
56. Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebocontrolled study. Arthritis Rheumatol 2014;66:S423-4
57. van der Heijde D, Landewe RBM, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2014;66:S424-5
58. Leonardi C, Matheson R, Zachariae CN, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
59. Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014;71:1176-82
60. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
61. Papp K, Menter A, Strober B, et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2015;72:436-9.e1
62. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014;71:1183-90e3
63. Genovese MC, Mease P, Greenwald MW, et al. Clinical response in subjects with psoriatic arthritis following one year of treatment with brodalumab, an anti-interleukin-17 receptor antibody. Arthritis Rheumatol 2014;66:S687
64. Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011;186:4481-9
65. Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol 2010;185:5688-91
66. Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 2014;133:1032-40
67. Zandvliet A, Glasgow S, Horowitz A, et al. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther 2015;53:139-46
68. Li Q, Ren G, Xu L, et al. Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model. Int Immunopharmacol 2014;21:119-27
69. Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med 2012;18:1750-1.. Different role of IL-23/IL-17 axis is human and mouse psoriasis.
70. Hao JQ. Targeting interleukin-22 in psoriasis. Inflammation 2014;37:94-9
71. Hua F, Comer GM, Stockert L, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol 2014;54:14-22
72. Solt LA, Kumar N, Nuhant P, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 2011;472:491-4.. Inhibition of RORgt for therapeutic purposes.
73. Chang MR, Lyda B, Kamenecka TM, Griffin PR. Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor g is therapeutic in the collagen-induced arthritis experimental model. Arthritis Rheumatol 2014;66:579-88
74. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8